慢性乙型肝炎患者抗病毒治疗前后临床指标的变化情况分析

Analysis of the Changing Clinical Indicators before and after Antiviral Treatment in Patients with Chronic Hepatitis B

目的:探讨应用抗病毒药物对慢性乙型肝炎患者实施诊治后产生的应用效果,并对治疗前后临床指标变化情况作出分析。方法:选择2019年8月到2020年11月期间因慢性乙型肝炎来院接受诊治的患者作为研究对象,共计纳入100例,运用随机抽签的方式将其平均分入常规组(n=50,接受常规治疗)和实验组(n=50,接受恩替卡韦治疗),对比治疗效果。结果:实验组治疗后肝功能各项指标、生活质量评分以及并发症发生率均优于常规组,P<0.05。结论:针对慢性乙型肝炎患者开展临床诊治期间,运用抗病毒药物恩替卡韦治疗后,对临床指标变化产生的影响较大,同时有助于改善患者生活质量,并发症发生率较低,安全性更高,适合普及推广。

Objective:To explore the application effect of antiviral drugs in the diagnosis and treatment of chronic hepatitis B patients,and to analyze the changes of clinical indicators before and after the treatment.Methods:Patients who came to the hospital for chronic hepatitis B from August 2019 to November 2020 were selected as the research objects.A total of 100 cases were included,and they were evenly divided into the conventional group(n=50,receiving conventional treatment)and the experimental group(n=50,receiving entecavir treatment)by random lottery to compare the treatment effect.Results:Liver function index,quality of life score and complication rate were better than the conventional group,with P<0.05.Conclusion:During the clinical diagnosis and treatment of chronic hepatitis B patients,the antiviral drug entecavir treatment has a great impact on the change of clinical indicators,and helps to improve the quality of life of patients,with a low complication rate and higher safety,which is suitable for popularization and promotion.